Global pharmaceutical and biotechnology companies are increasingly shifting their focus toward therapies that target the biological mechanisms of aging itself rather than simply treating symptoms. As interest grows in extending healthy lifespan, investment and research surrounding mRNA technologies, regenerative medicine, and cellular reprogramming platforms are accelerating worldwide.
Against this backdrop, Daewoong Pharmaceutical announced that it has secured key technology assets and rights from U.S. biotech company Turn Biotechnologies through a court-supervised asset auction. The company said it plans to accelerate research and development of therapies targeting age-related diseases based on the acquired platform technologies.
The core technology obtained by Daewoong Pharmaceutical is Turn Bio’s ERA platform, a partial reprogramming technology designed to restore cellular function by delivering reprogramming factors in mRNA form to aged cells. Unlike full cellular reprogramming approaches that may alter cellular identity, the technology aims to preserve the original characteristics of cells while selectively improving functional decline associated with aging.
In recent years, the global biotech industry has increasingly viewed aging as a controllable biological process rather than an inevitable natural phenomenon. Technologies involving cellular rejuvenation and regenerative medicine are drawing attention for their potential applications across ophthalmology, hearing disorders, and other degenerative diseases.
The acquisition also builds on research experience accumulated by HanAll Biopharma through previous collaboration with Turn Biotechnologies. HanAll had earlier explored the potential of age-related disease therapies through joint research initiatives and strategic cooperation involving both HanAll and Daewoong Pharmaceutical.
Daewoong Pharmaceutical said it plans to combine HanAll’s accumulated research expertise with its own R&D capabilities to expand development into ophthalmic and auditory aging-related indications. The company also aims to strengthen next-generation pipelines by integrating mRNA delivery technologies with disease-specific development strategies.
Industry observers say aging-control technologies are emerging as one of the most important long-term growth areas in the pharmaceutical and biotech sectors, driven by rapid global aging and growing demand for healthy lifespan extension. Investment and collaborative research in related fields have been expanding across the United States, Europe, and Asia as companies race to commercialize next-generation regenerative and anti-aging therapies.
